БИОХИМИЯ, 2021, том 86, вып. 2, с. 158–174

УДК 551.464.796+616.12

Белок клото и сердечно-сосудистая система*

Обзор

© 2021 И.Н. Тюренков 1, В.Н. Перфилова 1**vnperfilova@mail.ru; vnperfilova@gmail.com, А.А. Нестерова 2, Е.Ю. Глинка 3

1 Федеральное государственное бюджетное образовательное учреждение высшего образования «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской Федерации, 400066 Волгоград, Россия

2 Федеральное государственное бюджетное образовательное учреждение высшего образования «Пятигорский медико-фармацевтический институт» – филиал «Волгоградского государственного медицинского университета» Министерства здравоохранения Российской Федерации, 357500 Пятигорск, Россия

3 Keenan Research Centre, St. Michael's Hospital, Toronto, Canada

Поступила в редакцию 11.04.2020
После доработки 20.08.2020
Принята к публикации 08.09.2020

DOI: 10.31857/S0320972521020020

КЛЮЧЕВЫЕ СЛОВА: белок клото, сердечная недостаточность, ишемическая болезнь сердца, кардиомиопатии, артериальная гипертензия.

Аннотация

Белок клото влияет на многие метаболические процессы, играющие важную роль в развитии сердечно-сосудистых заболеваний. Он способен подавлять процессы перекисного окисления липидов, воспаление, предупреждать повреждение эндотелия, кальцификацию сосудов, повышение их ригидности, угнетать фиброзирование сердца. Уровень его экспрессии при многих заболеваниях снижается. Молекулярные механизмы, посредством которых клото осуществляет кардиопротекторное действие, основаны на его взаимодействии с рядом рецепторов и ионных каналов. Плейотропность этого белка делает его потенциальной мишенью в терапии сердечно-сосудистых заболеваний. В настоящем обзоре также приведены данные о лекарственных препаратах, стимулирующих экспрессию белка клото, и рассмотрены перспективы дальнейших исследований.

Текст статьи

Пожалуйста, введите код, чтобы получить PDF файл с полным текстом статьи:

captcha

Сноски

* Первоначально английский вариант рукописи опубликован на сайте «Biochemistry» (Moscow) http://protein.bio.msu.ru/biokhimiya, в рубрике «Papers in Press», BM20-098, 21.12.2020.

** Адресат для корреспонденции.

Конфликт интересов

Авторы заявляют об отсутствии конфликта интересов.

Соблюдение этических норм

Настоящая статья не содержит описания каких-либо исследований с участием людей или животных в качестве объектов.

Список литературы

1. Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., et al. (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing, Nature, 390, 45-51, doi: 10.1038/36285.

2. Shiraki-Iida, T., Aizawa, H., Matsumura, Y., Sekine, S., Iida, A., Anazawa, H., Nagai, R., Kuro-o, M., and Nabeshima, Y. (1998) Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein 1, FEBS Lett., 424, 6-10, doi: 10.1016/S0014-5793(98)00127-6.

3. Li, S.-A., Watanabe, M., Yamada, H., Nagai, A., Kinuta, M., and Takei, K. (2004) Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organsof mice, Cell Struct. Funct., 29, 91-99, doi: 10.1247/csf.29.91.

4. Lim, K., Groen, A., Molostvov, G., Lu, T., Lilley, K. S., Snead, D., James, S., Wilkinson, I. B., Ting, S., Hsiao, L. L., Hiemstra, T. F., and Zehnder, D. (2015) α-klotho expression in human tissues, J. Clin. Endocrinol. Metab., 100, 1308-1318, doi: 10.1210/jc.2015-1800.

5. Мельник А. А. (2017) Белок Klotho и фактор роста фибробластов FGF23 как маркеры хронической болезни почек, Почки, 6, 132-138.

6. Ito, S., Fujimori, T., Hayashizaki, Y., and Nabeshima Y. (2002) Identification of a novel mouse membrane-bound family 1 glycosidase-like protein, which carries an atypical active site structure, Biochim. Biophys. Acta, 1576, 341-345, doi: 10.1016/s0167-4781(02)00281-6.

7. Chen, G., Liu, Y., Goetz, R., Fu, L., Jayaraman, S., Hu, M. C., Moe, O. W., Liang, G., Li, X. and Mohammadi, M. (2018) α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signaling, Nature, 553, 461-466, doi: 10.1038/nature25451.

8. Xie, T., and Leung, P. S. (2017) Fibroblast growth factor 21: a regulator of metabolic disease and health span, Am. J. Physiol. Endocrinol. Metab., 313, E292-E302, doi: 10.1152/ajpendo.00101.2017.

9. Katoh, M., and Nakagama, H. (2014) FGF receptors: cancer biology and therapeutics, Med. Res. Rev., 34, 280-300, doi: 10.1002/med.21288.

10. Grabner, A., Amaral, A. P., Schramm, K., Singh, S., Sloan, A., et al. (2015) Activation of cardiac Fibroblast Growth Factor Receptor 4 causes left ventricular hypertrophy, Cell Metab., 22, 1020-1032, doi: 10.1016/j.cmet.2015.09.002.

11. Doi, S., Zou, Y., Toga, O., Pastor, J. V., John, G. B., Wang, L., Shiizaki, K., Gotschall, R., Schiavi, S., Yorioka, N., Takahashi, M., Boothman, D. A., and Kuro-o, M. (2011) Klotho inhibits Transforming Growth Factor-β1 (TGF-β1) signaling and suppresses renal fibrosis and cancer metastasis in mice, J. Biol. Chem., 286, 8655-8665, doi: 10.1074/jbc.M110.174037.

12. Lee, J., Jeong, D. J., Kim, J., Lee, S., Park, J. H., et al. (2010) The anti-aging gene KLOTHO is a novel target for epigenetic silencing in human cervical carcinoma, Mol. Cancer, 9, 109, doi: 10.1186/1476-4598-9-109.

13. Нестерова А. А., Глинка Е. Ю., Тюренков И. Н., Перфилова В. Н. (2020) Белок клото – универсальный регулятор физиологических процессов в организме, Успехи физиол. наук, 51, 88-104.

14. Ligumsky, H., Rubinek, T., Merenbakh-Lamin, K., Yeheskel, A., Sertchook, R., Shahmoon, S., Aviel-Ronen, S., and Wolf, I. (2015) Tumor suppressor activity of Klotho in breast cancer is revealed by structure–function analysis, Mol. Cancer Res., 13, 1398-1407, doi: 10.1158/1541-7786.MCR-15-0141.

15. Sopjani, M., Rinnerthaler, M., Kruja, J., and Dërmaku-Sopjani, M. (2015) Intracellular signaling of the aging suppressor protein Klotho, Curr. Mol. Med., 15, 27-37, doi: 10.2174/1566524015666150114111258.

16. Dalton, G., An, S.-W., Al-Juboori, S. I., Nischan, N., Yoon, J., et al. (2017) Soluble klotho binds monosialoganglioside to regulate membrane microdomains and growth factor signaling, Proc. Natl. Acad. Sci. USA, 114, 752-757, doi: 10.1073/pnas.1620301114.

17. Wolf, M. T., An, S. W., Nie, M., Bal, M. S., and Huang, C. L. (2014) Klotho up-regulates renal calcium channel transient receptor potential vanilloid 5 (TRPV5) by intra- and extracellular N-glycosylation-dependent mechanisms, J. Biol. Chem., 289, 35849-35857, doi: 10.1074/jbc.M114.616649.

18. Wright, J. D., An, S. W., Xie, J., Lim, C., and Huang, C. L. (2019) Soluble klotho regulates TRPC6 calcium signaling via lipid rafts, independent of the FGFR-FGF23 pathway, FASEB J., 33, 9182-9193, doi: 10.1096/fj.201900321R.

19. Wright, J. D., An, S.-W., Xie, J., Yoon, J., Nischan, N., Kohler, J. J., Oliver, N., Lim, C., and Huang, C. L. (2017) Modeled structural basis for the recognition of α2-3-sialyllactose by soluble Klotho, FASEB J., 31, 3574-3586, doi: 10.1096/fj.201700043R.

20. Zhang, J., Gupte, J., Gong, Y., Weiszmann, J., Zhang, Y., Lee, K. J., Richards, W. G., and Lia, Y. (2017) Over-expression of fibroblast growth factor 21 increases bile acid biosynthesis by opposing FGF15/19 action, EBioMedicine, 15, 173-183, doi: 10.1016/j.ebiom.2016.12.016.

21. Patel, V., Adya, R., Chen, J., Ramanjaneya, M., Bari, M. F., Bhudia, S. K., Hillhouse, E. W., Tan, B. K., and Randeva, H. S. (2014) Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts, PLoS One, 9, e87102, doi: 10.1371/journal.pone.0087102.

22. Lee, S., Choi, J., Mohanty, J., Sousa, L. P., Tome, F., Pardon, E., Steyaert, J., Lemmon, M. A., Lax, I., and Schlessinger, J. (2018) Structures of β-Klotho reveal a ‘zip code’-like mechanism for endocrine FGF signaling, Nature, 553, 501-505, doi: 10.1038/nature25010.

23. Kuzina, E. S., Ung, P. M., Mohanty, J., Tome, F., Choi, J., Pardon, E., Steyaert, J., Lax, I., Schlessinger, A., Schlessinger, J., and Lee, S. (2019) Structures of ligand-occupied β-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity, PNAS, 116, 7819-7824, doi: 10.1073/pnas.1822055116.

24. Rubinek, T., Shahmoon, S., Shabtay-Orbach, A., Ben Ami, M., Levy-Shraga, Y., et al. (2016) Klotho response to treatment with growth hormone and the role of IGF-I as a mediator, Metabolism, 65, 1597-1604, doi: 10.1016/j.metabol.2016.08.004.

25. Chen, C. D., Podvin, S., Gillespie, E., Leeman, S. E., and Abraham C. R. (2007) Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17, Proc. Natl. Acad. Ssi. USA, 104, 19796-19801, doi: 10.1073/pnas.0709805104.

26. Kim, J. H., Hwang, K. H., Park, K. S., Kong, I. D., and Cha, S. K. (2015) Biological role of anti-aging protein klotho, J. Lifestyle Med., 5, 1-6, doi: 10.15280/jlm.2015.5.1.1.

27. Kuro-o, M. (2009) Klotho and aging, Biochim. Biophys. Acta, 1790, 1049-1058, doi: 10.1016/j.bbagen.2009.02.005.

28. Cui, W., Leng, B., and Wang, G. (2019) Klotho protein inhibits H2O2-induced oxidative injury in endothelial cells via regulation of PI3K/AKT/Nrf2/HO-1 pathways, Can. J. Physiol. Pharmacol., 97, 370-376, doi: 10.1139/cjpp-2018-0277.

29. Zhang, W., Xue, D., Hu, D., Xie, T., Tao, Y., Zhu, T., Chen, E., and Pan, Z. (2015) Secreted klotho protein attenuates osteogenic differentiation of human bone marrow mesenchymal stem cells in vitro via inactivation of the FGFR1/ERK signaling pathway, Growth Factors, 33, 356-365, doi: 10.3109/08977194.2015.1108313.

30. Abramovitz, L., Rubinek, T., Ligumsky, H., Bose, S., Barshack, I., Avivi, C., Kaufman, B., and Wolf, I. (2011) KL1 internal repeat mediates Klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer, Clin. Cancer Res., 17, 4254-4266, doi: 10.1158/1078-0432.CCR-10-2749.

31. Neyra, J. A., and Hu, M. C. (2017) Potential application of klotho in human chronic kidney disease, Bone, 100, 41-49, doi: 10.1016/j.bone.2017.01.017.

32. Mencke, R., Harms, G., Moser, J., van Meurs, M., Diepstra, A., Leuvenink, H. G., and Hillebrands, J. L. (2017) Human alternative Klotho mRNA is a nonsense-mediated mRNA decay target inefficiently spliced in renal disease, JCI Insight, 2, e94375, doi: 10.1172/jci.insight.94375.

33. Xu, Y., and Sun, Z. (2017) Regulation of S-formylglutathione hydrolase by the anti-aging gene klotho, Oncotarget, 8, 88259-88275, doi: 10.18632/oncotarget.19111.

34. Tacer, K. F., Bookout, A. L., Ding, X. S., Kurosu, H., John, G. B., Wang, L., Goetz, R., Mohammadi, M., Kuro-o, M., Mangelsdorf, D. J., and Kliewer, S. A. (2010) Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse, Mol. Endocrinol., 24, 2050-2064, doi: 10.1210/me.2010-0142.

35. Tomlinson, E., Fu, L., John, L., Hultgren, B., Huang, X., Renz, M., Stephan, J. P., Tsai, S. P., Powell-Braxton, L., French, D., and Stewart, T. A. (2002) Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity, Endocrinology, 143, 1741-1747, doi: 10.1210/endo.143.5.8850.

36. Nakayama, Y., Miyake, A., Nakagawa, Y., Mido, T., Yoshikawa, M., Konishi, M., and Itoh, N. (2008) Fgf19 is required for zebrafish lens and retina development, Dev. Biol., 313, 752-766, doi: 10.1016/j.ydbio.2007.11.013.

37. Kurose, H., Okamoto, M., Shimizu, M., Bito, T., Marcelle, C., Noji, S., and Ohuchi, H. (2005) FGF19-FGFR4 signaling elaborates lens induction with the FGF8-L-Maf cascade in the chick embryo, Dev. Growth Differ., 47, 213-223, doi: 10.1111/j.1440-169X.2005.00795.x.

38. Dinh, Q. N., Drummond, G. R., Sobey, C. G., and Chrissobolis, S. (2014) Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension, Biomed. Res. Int., 2014, 406960, doi: 10.1155/2014/406960.

39. Förstermann, U., Xia, N., and Li, H. (2017) Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis, Circ. Res., 120, 713-735, doi: 10.1161/CIRCRESAHA.116.309326.

40. Yamamoto, M., Clark, J. D., Pastor, J. V., Gurnani, P., Nandi, A., Kurosu, H., Miyoshi, M., Ogawa, Y., Castrillon, D. H., Rosenblatt, K. P., and Kuro-o, M. (2005) Regulation of oxidative stress by the anti-aging hormone klotho, J. Biol. Chem., 280, 38029-38034, doi: 10.1074/jbc.M509039200.

41. Wang, Y., Zhou, Y., and Graves, D. T. (2014) FOXO transcription factors: their clinical significance and regulation, Biomed. Res. Int., 2014, 925350, doi: 10.1155/2014/925350.

42. Kawamori, D., Kaneto, H., Nakatani, Y., Matsuoka, T. A., Matsuhisa, M., Hori, M., and Yamasaki, Y. (2006) The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation, J. Biol. Chem., 281, 1091-1098, doi: 10.1074/jbc.M508510200.

43. Ju, Y., Xu, T., Zhang, H., and Yu, A. (2014) FOXO1-dependent DNA damage repair is regulated by JNK in lung cancer cells, Int. J. Oncol., 44, 1284-1292, doi: 10.3892/ijo.2014.2269.

44. Zhao, H. F., Wang, J., and Tony To, S.-S. (2015) The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance or contradiction? Int. J. Oncol., 47, 429-436, doi: 10.3892/ijo.2015.3052.

45. Sunayama, J., Tsuruta, F., Masuyama, N., and Gotoh, Y. (2005) JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3, J. Cell. Biol., 170, 295-304, doi: 10.1083/jcb.200409117.

46. Essers, M. A., Weijzen, S., de Vries-Smits, A. M., Saarloos, I., de Ruiter, N. D., Bos, J. L., and Burgering, B. M. (2004) FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK, EMBO J., 23, 4802-4812, doi: 10.1038/sj.emboj.7600476.

47. Essers, M. A., de Vries-Smits, L. M., Barker, N., Polderman, P. E., Burgering, B. M., and Korswagen, H. C. (2005) Functional interaction between beta-catenin and FOXO in oxidative stress signaling, Science, 308, 1181-1184, doi: 10.1126/science.1109083.

48. Yao, Y., Wang, Y., Zhang, Y., and Liu, C. (2017) Klotho ameliorates oxidized low density lipoprotein (Ox-LDL)-induced oxidative stress via regulating LOX-1 and PI3K/Akt/eNOS pathways, Lipids Health Dis., 16, 77, doi: 10.1186/s12944-017-0447-0.

49. Yang, K., Nie, L., Huang, Y., Zhang, J., Xiao, T., Guan, X., and Zhao, J. (2012) Amelioration of uremic toxin indoxyl sulfate-induced endothelial cell dysfunction by Klotho protein, Toxicol. Lett., 215, 77-83, doi: 10.1016/j.toxlet. 2012.10.004.

50. Chung, C. P., Chang, Y. C., Ding, Y., Lim, K., Liu, Q., Zhu, L., Zhang, W., Lu, T. S., Molostvov, G., Zehnder, D., and Hsiao, L. L. (2017) α-Klotho expression determines nitric oxide synthesis in response to FGF23 in human aortic endothelial cells, PLoS One, 12, e0176817, doi: 10.1371/journal.pone.0176817.

51. Prud’homme, G. J., Glinka, Y., Kurt, M., Liu, W., and Wang, Q. (2017) The anti-aging protein Klotho is induced by GABA therapy and exerts protective and stimulatory effects on pancreatic beta cells, Biochem. Biophys. Res. Commun., 493, 1542-1547, doi: 10.1016/j.bbrc.2017.10.029.

52. Kusaba, T., Okigaki, M., Matui, A., Murakami, M., Ishikawa, K., et al. (2010) Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity, Proc. Natl. Acad. Sci. USA, 107, 19308-19313, doi: 10.1073/pnas.1008544107.

53. Semba, R. D., Cappola, A. R., Sun, K., Bandinelli, S., Dalal, M., Crasto, C., Guralnik, J. M., and Ferrucci, L. (2011) Plasma klotho and cardiovascular disease in adults, J. Am. Geriatr. Soc., 59, 1596-1601, doi: 10.1111/j.1532-5415.2011.03558.x.

54. Kokkinaki, M., Abu-Asab, M., Gunawardena, N., Ahern, G., Javidnia, M., Young, J., and Golestaneh, N. (2013) Klotho regulates retinal pigment epithelial functions and protects against oxidative stress, J. Neurosci., 33, 16346-16359, doi: 10.1523/JNEUROSCI.0402-13.2013.

55. Zhao, Y., Meng, C., Wang, Y., Huang, H., Liu, W., Zhang, J. F., Zhao, H., Feng, B., Leung, P. S., and Xi, Y. (2016) IL-1 inhibits Klotho expression and FGF19 signaling in hepatocytes, Physiol. Endocrinol. Metab., 310, E289-300, doi: 10.1152/ajpendo.00356.2015.

56. Prud’homme, G. J., Glinka, Y., Kurt, M., Liu, W., and Wang, Q. (2020) Systemic Klotho therapy protects against insulitis and enhances beta-cell mass in NOD mice, Biochem. Biophys. Res. Commun., 525, 693-698, doi: 10.1016/j.bbrc.2020.02.123.

57. Navarro-González, J. F., Donate-Correa, J., Muros de Fuentes, M., Pérez-Hernández, H., Martínez-Sanz, R., and Mora-Fernández, C. (2014) Reduced Klotho is associated with the presence and severity of coronary artery disease, Heart, 100, 34-40, doi: 10.1136/heartjnl-2013-304746.

58. Bergmark, B. A., Udell, J. A., Morrow, D. A., Jarolim, P., Kuder, J. F., Solomon, S. D., Pfeffer, M. A., Braunwald, E., and Sabatine, M. S. (2019) Klotho, fibroblast growth factor-23, and the renin-angiotensin system – an analysis from the PEACE trial, Eur. J. Heart Fail., 21, 462-470, doi: 10.1002/ejhf.1424.

59. Faul, C., Amaral, A. P., Oskouei, B., Hu, M. C., Sloan, A., and Isakova, T. (2011) FGF23 induces left ventricular hypertrophy, J. Clin. Invest., 121, 4393-4408, doi: 10.1172/JCI46122.

60. Xie, J., Yoon, J., An, S.-W., Kuro-o, M., and Huang, C.-L. (2015) Soluble klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate, J. Am. Soc. Nephrol., 26, 1150-1160, doi: 10.1681/ASN.2014040325.

61. Zhou, X., Li, S., Wang, Z., Yu, L., and Jiang, H. (2015) Klotho protein: a potential therapeutic agent during myocardial ischemia and reperfusion, Int. J. Cardiol., 191, 227-228, doi: 10.1016/j.ijcard.2015.05.029.

62. Takeshita, K., Fujimori, T., Kurotaki, Y., Honjo, H., Tsujikawa, H., et al. (2004) Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression, Circulation, 109, 1776-1782, doi: 10.1161/01.CIR.0000124224.48962.32.

63. Dermaku-Sopjani, M., Sopjani, M., Saxena, A., Shojaiefard, M., Bogatikov, E., Alesutan, I., Eichenmüller, M., and Lang, F. (2011) Downregulation of NaPi-IIa and NaPi-IIb Na-coupled phosphate transporters by coexpression of Klotho, Cell Physiol. Biochem., 28, 251-258, doi: 10.1159/000331737.

64. Hu, M. C., Shi, M., Zhang, J., Pastor, J., Nakatani, T., and Lanske, B. (2010) Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule, FASEB J., 24, 3438-3450, doi: 10.1096/fj.10-154765.

65. Sopjani, M., Alesutan, I., Dermaku-Sopjani, M., Gu, S., Zelenak, C., Munoz, C., Velic, A., Föller, M., Rosenblatt, K. P., Kuro-o, M., and Lang, F. (2011) Regulation of the Na+/K+-ATPase by Klotho, FEBS Lett., 585, 1759-1764, doi: 10.1016/j.febslet.2011.05.021.

66. Boros, S., Bindels, R. J., and Hoenderop, J. G. (2009) Active Ca(2+) reabsorption in the connecting tubule, Pflugers Arch., 458, 99-109, doi: 10.1007/s00424-008-0602-6.

67. Munoz, C., Pakladok, T., Almilaji, A., Elvira, B., Seebohm, G., Voelkl, J., Föller, M., Shumilina, E., and Lang, F. (2013) Klotho sensitivity of the hERG channel, FEBS Lett., 587, 1663-1668, doi: 10.1016/j.febslet.2013.04.011.

68. Kaess, B. M., Rong, J., Larson, M. G., Hamburg, N. M., Vita, J. A., Levy, D., Benjamin, E. J., Vasan, R. S., and Mitchell, G. F. (2012) Aortic stiffness, blood pressure progression, and incident hypertension, JAMA, 308, 875-881, doi: 10.1001/2012.jama.10503.

69. Cavalcante, J. L., Lima, J. A., Redheuil, A., and Al-Mallah, M. H. (2011) Aortic stiffness: current understanding and future directions, J. Am. Coll. Cardiol., 57, 1511-1522, doi: 10.1016/j.jacc.2010.12.017.

70. Gao, D., Zuo, Z., Tian, J., Ali, Q., Lin, Y., Lei, H., and Sun, Z. (2016) Activation of SIRT1 attenuates klotho deficiency-induced arterial stiffness and hypertension by enhancing AMP-activated protein kinase activity, Hypertension, 68, 1191-1199, doi: 10.1161/HYPERTENSIONAHA.116.07709.

71. Mencke, R., and Hillebrands, J.-L. (2016) The Role of the anti-ageing protein klotho in vascular physiology and pathophysiology, Nature, 553, 461-466, doi: 10.1016/j.arr.2016.09.001.

72. Chen, K., and Sun, Z. (2019) Autophagy plays a critical role in Klotho gene deficiency-induced arterial stiffening and hypertension, J. Mol. Med. (Berl), 97, 1615-1625, doi: 10.1007/s00109-019-01841-6.

73. Zhou, X., Chen, K., Wang, Y., Schuman, M., Lei, H., and Sun, Z. (2016) Antiaging gene Klotho regulates adrenal CYP11B2 expression and aldosterone synthesis, JASN, 27, 1765-1776, doi: 10.1681/ASN.2015010093.

74. Hu, M. C., Shi, M., Gillings, N., Flores, B., Takahashi, M., Kuro-O, M., and Moe, O. W. (2017) Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy, Kidney Int., 91, 1104-1114, doi: 10.1016/j.kint.2016.10.034.

75. Xie, J., Cha, S. K., An, S. W., Kuro-O, M., Birnbaumer, L., and Huang, C. L. (2012) Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart, Nat. Commun., 3, 123, doi: 10.1038/ncomms2240.

76. Wu, X., Eder, P., Chang, B., and Molkentin, J. D. (2010) TRPC channels are necessary mediators of pathologic cardiac hypertrophy, Proc. Natl. Acad. Sci. USA, 107, 7000-7005, doi: 10.1073/pnas.1001825107.

77. Eder, P., and Molkentin, J. D. (2011) TRPC channels as effectors of cardiac hypertrophy, Circ. Res., 108, 265-272, doi: 10.1161/CIRCRESAHA.110.225888.

78. Hu, M. C., Shi, M., Zhang, J., Quiñones, H., Griffith, C., Kuro-O, M., and Moe, O. W. (2011) Klotho deficiency causes vascular calcification in chronic kidney disease, J. Am. Soc. Nephrol., 22, 124-136, doi: 10.1681/ASN.2009121311.

79. Yamada, S., and Giachelli, C. M. (2017) Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho, Bone, 100, 87-93, doi: 10.1016/j.bone.2016.11.012.

80. Lindberg, K., Olauson, H., Amin, R., Ponnusamy, A., Goetz, R., Taylor, R. F., Mohammadi, M., Canfield, A., Kublickiene, K., and Larsson, T. E. (2013) Arterial klotho expression and FGF23 effects on vascular calcification and function, PLoS One, 8, e60658, doi: 10.1371/journal.pone.0060658.

81. Lim, K., Lu, T. S., Molostvov, G., Lee, C., Lam, F. T., Zehnder, D., and Hsiao, L. L. (2012) Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23, Circulation, 125, 2243-2255, doi: 10.1161/CIRCULATIONAHA.111.053405.

82. Jimbo, R., Kawakami-Mori, F., Mu, S., Hirohama, D., Majtan, B., Shimizu, Y., Yatomi, Y., Fukumoto, S., Fujita, T., and Shimosawa, T. (2014) Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency, Kidney Int., 85, 1103-1111, doi: 10.1038/ki.2013.332.

83. Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., and Yamashita, T. (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism, J. Clin. Invest. 113, 561-568, doi: 10.1172/JCI19081.

84. Zhao, Y., Zhao, M. M., Cai, Y., Zheng, M. F., Sun, W. L., Zhang, S. Y., Kong, W., Gu, J., Wang, X., and Xu, M. J. (2015) Mammalian target of rapamycin signaling inhibition ameliorates vascular calcification via Klotho upregulation, Kidney Int., 88, 711-721, doi: 10.1038/ki.2015.160.

85. Chang, J. R., Guo, J., Wang, Y., Hou, Y. L., Lu, W. W., et al. (2016) Intermedin1-53 attenuates vascular calcification in rats with chronic kidney disease by upregulation of α-Klotho, Kidney Int., 89, 586-600, doi: 10.1016/j.kint.2015.12.029.

86. Agarwal, I., Ide, N., Ix, J. H., Kestenbaum, B., Lanske, B., Schiller, N. B., Whooley, M. A., and Mukamal, K. J. (2014) Fibroblast growth factor-23 and cardiac structure and function, J. Am. Heart Assoc., 3, e000584, doi: 10.1161/JAHA.113.000584.

87. Hu, M. C., Shi, M., Cho, H. J., Adams-Huet, B., Paek, J., et al. (2015) Klotho and phosphate are modulators of pathologic uremic cardiac remodeling, J. Am. Soc. Nephrol., 26, 1290-1302, doi: 10.1681/ASN.2014050465.

88. Jia, Z., Wei, L., Liu, Q., Zhu, Z., Yang, J., Yang, X., Gan, S., Chen, W., and Zhang, L. (2015) Impact of transfection with recombinant adenovirus vector-mediated Klotho gene on myocardial remodeling in a rat model of heart failure, Zhonghua Xin Xue Guan Bing Za Zhi, 43, 219-226.

89. Tang, G., Shen, Y., Gao, P., Song, S. S., and Si, L. Y. (2018) Klotho attenuates isoproterenol-induced hypertrophic response in H9C2 cells by activating Na+/K+-ATPase and inhibiting the reverse mode of Na+/Ca2+-exchanger, In Vitro Cell Dev. Biol. Anim., 54, 250-256, doi: 10.1007/s11626-017-0215-5.

90. Москалёв А. В., Рудой А. С., Апчел А. В., Зуева В. О., Казымова О. Э. (2016) Особенности биологии трансформирующего ростового фактора β и иммунопатология, Вестн. РВМА, 54, 206-216.

91. Заславская Е. Л., Морозов А. Н., Ионин В. А., Ма И., Нифонтов С. Е., Баранова Е. И., Яшин С. М., Шляхто Е. В. (2018) Роль трансформирующего фактора роста бета1 и галектина-3 в формировании фиброза левого предсердия у пациентов с пароксизмальной формой фибрилляции предсердий и метаболическим синдромом, Рос. кардиол. ж., 154, 60-66.

92. Корженевская К. В., Гавришева Н. А., Панов А. В., Сесь Т. П., Алугишвили М. З., Козлов В. В. (2010) Трансформирующий фактор роста-β1 при различном клиническом течении ишемической болезни сердца после операции коронарного шунтирования, Мед. иммунология, 12, 521-528.

93. Inoue, N., Maeda, R., Kavakami, H., Shokawa, T., Yamamoto, H., Ito, C., and Sasaki, H. (2009) Aortic pulse wave velocity predicts cardiovascular mortality in middle-aged and elderly Japanese men, Circ. J., 73, 549-553, doi: 10.1253/circj.cj-08-0492.

94. Ding, J., Tang, Q., Luo, B., Zhang, L., Lin, L., Han, L., Hao, M., Li, M., Yu, L., and Li, M. (2019) Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway, Eur. J. Pharmacol., 859, 172549, doi: 10.1016/j.ejphar.2019.172549.

95. Ucar, A., Gupta, S. K., Fiedler, J., Erikci, E., Kardasinski, M., et al. (2012) The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy, Nat. Commun., 3, 1078, doi: 10.1038/ncomms2090.

96. Chen, Q., Zhang, H., Liu, Y., Adams, S., Eilken, H., Stehling, M., Corada, M., Dejana, E., Zhou, B., and Adams, R. H. (2016) Endothelial cells are progenitors of cardiac pericytes and vascular smooth muscle cells, Nat. Commun., 7, 12422, doi: 10.1038/ncomms12422.

97. Arking, D. E., Becker, D. M., Yanek, L. R., Fallin, D., Judge, D. P., Moy, T. F., Becker, L. C., and Dietz, H. C. (2003) KLOTHO allele status and the risk of early-onset occult coronary artery disease, Am. J. Hum. Genet., 72, 1154-1161, doi: 10.1086/375035.

98. Majumdar, V., Nagaraja, D., and Christopher, R. (2010) Association of the functional KL-VS variant of Klotho gene with early-onset ischemic stroke, Biochem. Biophys. Res. Commun., 403, 412-416, doi: 10.1016/j.bbrc.2010.11.045.

99. Oguro, R., Kamide, K., Kokubo, Y., Shimaoka, I., Congrains, A., et al. (2010) Association of carotid atherosclerosis with genetic polymorphisms of the klotho gene in patients with hypertension, Geriatr. Gerontol. Int., 10, 311-318, doi: 10.1111/j.1447-0594.2010.00612.x.

100. Imamura, A., Okumura, K., Ogawa, Y., Murakami, R., Torigoe, M., Numaguchi, Y., and Murohara, T. (2006) Klotho gene polymorphism may be a genetic risk factor for atherosclerotic coronary artery disease but not for vasospastic angina in Japanese, Clin. Chim. Acta., 371, 66-70, doi: 10.1016/j.cca.2006.02.021.

101. Majumdar, V., Jose, D., and Christopher, R. (2011) Influence of Klotho genotypes on plasma NO(x) levels in South Indian population, Thromb Res., 128, 251-255, doi: 10.1016/j.thromres.2011.04.002.

102. Pavlatou, M. G., Remaley, A. T., and Gold, P. W. (2016) Klotho: a humeral mediator in CSF and plasma that influences longevity and susceptibility to multiple complex disorders, including depression, Transl. Psychiatry, 6, e876, doi: 10.1038/tp.2016.135.

103. Qiu, X., Guo, Q., Xiong, W., Yang, X., and Tang, Y. Q. (2016) Therapeutic effect of astragaloside-IV on bradycardia is involved in up-regulating klotho expression, Life Sci., 144, 94-102, doi: 10.1016/j.lfs.2015.11.021.

104. Narumiya, H., Sasaki, S., Kuwahara, N., Irie, H., Kusaba, T., Kameyama, H., Tamagaki, K., Hatta, T., Takeda, K., and Matsubara, H. (2004) HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells, Cardiovasc. Res., 64, 331-336, doi: 10.1016/j.cardiores.2004.07.011.

105. Yoon, H. E., Ghee, J. Y., Piao, S., Song, J. H., Han, D. H., Kim, S., Ohashi, N., Kobori, H., Kuro-O, M., and Yang, C. W. (2011) Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy, Nephrol. Dial. Transplant., 26, 800-813, doi: 10.1093/ndt/gfq537.

106. Cheng, L., Zhang, L., Yang, J., and Hao, L. (2017) Activation of peroxisome proliferator-activated receptor γ inhibits vascular calcification by upregulating Klotho, Exp. Ther. Med., 13, 467-474, doi: 10.3892/etm.2016.3996.

107. Haussler, M. R., Whitfield, G. K., Haussler, C. A., Sabir, M. S., Khan, Z., Sandoval, R., and Jurutka, P. W. (2016) 1,25-Dihydroxyvitamin D and Klotho: A tale of two renal hormones coming of age, Vitam. Horm., 100, 165-230, doi: 10.1016/bs.vh.2015.11.005.

108. Lorenzi, O., Veyrat-Durebex, C., Wollheim, C. B., Villemin, P., Rohner-Jeanrenaud, F., Zanchi, A., and Vischer, U. M. (2010) Evidence against a direct role of klotho in insulin resistance, Pflugers Arch., 459, 465-473, doi: 10.1007/s00424-009-0735-2.

109. Bilan, V. P., Salah, E. M., Bastacky, S., Jones, H. B., Mayers, R. M., Zinker, B., Poucher, S. M., and Tofovic, S.P. (2011) Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats, J. Endocrinol., 210, 293-308, doi: 10.1530/JOE-11-0122.

110. Dagenais, G. R., Gerstein, H. C., Holman, R., Budaj, A., Escalante, A., et al. (2008) Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) Trial, Diabetes Care, 31, 1007-1014, doi: 10.2337/dc07-1868.